CAS: 154447-36-6; 2-Morpholino-8-Phenyl-4H-Chromen-4-One
该化合物是一种合成有机化合物,其复杂结构特征包括苯丙丙烯核心,苯基组和氨基替代物,该化合物通常具有与氟氯素有关的特性,例如潜在的抗氧化活动,并可能因其独特的功能组而与各种生物目标发生相互作用.光伏环有助于其溶解性,并可能加强其药用特性.它经常被研究其在药用化学中的潜在应用,特别是在治疗剂的开发中.该化合物的稳定性,再活性和溶性可因环境条件和其他化学物种的存在而不同.与许多有机化合物一样,其在生物系统中的行为可能受到诸如pH,温度和酶的存在等因素的影响.
- 英文名称2-Morpholino-8-Phenyl-4H-Chromen-4-One
- 中文名称2-吗啉代-8-苯基色酮
- IUPAC名称2-morpholino-8-phenyl-4H-chromen-4-one
- 其它别名8-Phenyl-2-(morpholin-4-yl)-chromen-4-one
- CAS编号154447-36-6
- MFCD编号:MFCD00270881
- EINECS号:960-639-4
- FDA UNII编号:31M2U1DVID
- 分子式:C19H17NO3分子量:307.35
- 产品CID: 761844
- 同类组份化合物CAS154447-36-6 (free base)934389-88-5 (HCl)
- 产品分类生物化工 → 抑制剂 → PI3K/Akt/mTOR抑制剂(PI3K/Akt/mTOR)
物理性质
- 熔点182-184 °C
- 沸点494.6±45.0 °C at 760 mmHg
- 闪点253.0±28.7 °C
- 密度1.3±0.1 g/cm3
- pKa:0.55±0.20(预测)
- PSA:42.68
- LogP:3.82
- 折射率1.627
- 蒸汽压0.0±1.3 mmHg at 25°C
- 溶解性DMSO: >5 mg/mL
- 外观形态白色至类白色固体
- 储存条件密封干燥,冷冻保存, 低于 -20°C
- 产品应用该化合物是一种磷酸丁酯3-KINASE(PI3K)抑制剂,它阻断了松鼠骨髓腔内肿瘤组织形成,并废除了多种骨质瘤(MM)引起的骨质激素形成和骨吸附;它抑制了肿瘤生长,并诱发活性血管的吸附,特别是在洛沃肿瘤中,这在恶性肿瘤的尿模型中显示出显著的功效;它明显抑制了卵巢癌的生长和形成;在体外,它抑制各种癌症细胞的扩散,包括结肠癌,卵巢癌症,乳腺瘤和MG-63骨科瘤细胞,诱发G1细胞循环阻塞,核凝聚和细胞体积减少,以及低温调节磷酸亚基(SER473表);它还阻塞了针对CK2(IC50=98 NM)和DNA-PK(IC50 =1.4M)的气成形和气压活动.
MSDS等安全信息
欧盟法规
C&L通报上下游产品
phenylboronic acid trifluoromethanesulfonic acid 2-(morpholin-4-yl)-4-oxo-4H-chromen-8-yl ester 1-(2-hydroxy-3-phenylphenyl)-3-(morpholin-4-yl)-propane-1,3-dione 4-acetylmorpholine 040-70A040-70 28H23N2O5S(1+)*I(1-)C28H23N2O5S(1+)*I(1-) 28H23N2O5(1+)C28H23N2O5(1+)合成工艺路线路线简述
📜2-羟基-3-苯基苯甲酸甲酯置于三氟甲磺酸酐,Lithium Diisopropyl Amide体系中,用 四氢呋喃,正己烷,二氯甲烷 用作溶剂,化学反应 37.5H,反应生成2-吗啉代-8-苯基色酮
参考文献:Dna依赖性蛋白激酶的选择性苯并吡喃酮和嘧啶[2,1-A]异喹啉-4-酮抑制剂:合成,结构活性研究和体外人类肿瘤细胞系的放射增敏作用.
标题:Dna依赖性蛋白激酶的选择性苯并吡喃酮和嘧啶[2,1-A]异喹啉-4-酮抑制剂:合成,结构活性研究和体外人类肿瘤细胞系的放射增敏作用.
摘要:合成了各种各样的chromen-2-One,Chromen-4-One和pyrimidoisoquinolin-4-One衍生物,并评估了其对dna修复酶dna依赖性蛋白激酶(dna-Pk)的抑制活性,目的是阐明效价和激酶选择性的构效关系.Dna-Pk抑制活性在评估的一系列化合物(ic(50)值范围从0.19到> 10 Microm)上有很大差异,其中7,8-苯并铬基-4-酮和嘧啶基[2,1]表现出优异的活性.-A] Isoquinolin-4-One模板.相比之下,基于苯并色素-2-酮(香豆素)或2-芳基-7,8-苯并色素-4-酮(黄酮)支架的抑制剂效力较低.至关重要的是,这些研究揭示了在苯并吡喃酮和嘧啶基2位上的结构活性关系非常受约束[2,1-A]异喹啉-4-酮药效基团,在此位置仅可耐受2-吗啉代或2-(2'-甲基吗啉代)基团.用最有效的抑制剂nu7163(48; Ic(50)= 0
Doi:10.1021/jm049526A
海关参考信息
- 2902200000-苯
2909110000-乙醚
2922110001-单乙醇胺
2921199090-其他无环单胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound
专利号:US-2009227575-A1
优先权日:2008-03-04
标 题 :7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
发明人：VENKATESAN ARANAPAKAM MUDUMBAI; CHEN ZECHENG; DOS SANTOS OSVALDO; BROOIJMANS NATASJA; GOPALSAMY ARIAMALA
权利人:WYETH CORP
摘要:A 7H-pyrrolo[2,3-h]quinazoline compound of the formula I n n n n n n n n n n wherein Ar, R 1 , R 2 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and n are as defined in the specification, and methods for making same.
专利号:US-11299491-B2
优先权日:2018-11-16
标 题:Synthesis of key intermediate of KRAS G12C inhibitor compound
专利号:US-2025206735-A1
优先权日:2018-11-16
标题:Synthesis of key intermediate of kras g12c inhibitor compound
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Welling A, Hofmann F, Wegener JW. Inhibition of L-type Cav1.2 Ca2+ channels by 2,(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) and 2-[1-(3-dimethyl-aminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl) maleimide (Go6983). Mol Pharmacol. 2005 Feb;67(2):541-4. Epub 2004 Nov 10.
8: Smith LK, Vlahos CJ, Reddy KK, Falck JR, Garner CW. Wortmannin and LY294002 inhibit the insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes. Mol Cell Endocrinol. 1995 Aug 30;113(1):73-81.
合成参考文献
参考文献:10.1128/mcb.01247-09
摘要:Liu F, Jia L, Thompson-Baine A, Puglise JM, ter Beest MBA, Zegers MMP. Cadherins and Pak1 Control Contact Inhibition of Proliferation by Pak1-βPIX-GIT Complex-Dependent Regulation of Cell-Matrix Signaling. Molecular and Cellular Biology. 2010 Apr 01;30(8):1971–83. doi: 10.1128/mcb.01247-09.
参考文献:10.1007/s10735-010-9253-y
摘要:Jeanes A, Smutny M, Leerberg JM, Yap AS. Phosphatidylinositol 3′-kinase signalling supports cell height in established epithelial monolayers. Journal of Molecular Histology. 2009 Oct;40(5-6):395–405. doi: 10.1007/s10735-010-9253-y.
参考文献:10.1016/j.devcel.2009.11.015
摘要:Yoo SK, Deng Q, Cavnar PJ, Wu YI, Hahn KM, Huttenlocher A. Differential Regulation of Protrusion and Polarity by PI(3)K during Neutrophil Motility in Live Zebrafish. Developmental Cell. 2010 Feb;18(2):226–36. doi: 10.1016/j.devcel.2009.11.015.
参考文献:10.1186/1471-2199-12-29
摘要:Wen X, Chao C, Ives K, Hellmich MR. Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells. BMC Molecular and Cell Biology. 2011 Jul 11;12(1):29. doi: 10.1186/1471-2199-12-29.
参考文献:10.1186/ar3398
摘要:Heo YJ, Oh HJ, Jung YO, Cho ML, Lee SY, Yu JG, Park MK, Kim HR, Lee SH, Park SH, Kim HY. The expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1. Arthritis Res Ther. 2011 Jul 12;13(4):R113.
📝 需求与反馈
尽可能描述清楚需求与问题信息
